Vamorolone, also known as VBP15, is a synthetic glucocorticoid used as an antiinflammatory and immunosuppressant agent in the management of Duchenne muscular dystrophy (DMD). Vamorolone is a synthetic corticosteroid that acts as an agonist at the glucocorticoid receptor to exert anti-inflammatory and immunosuppressive effects. It is also an antagonist of the mineralocorticoid receptor. The precise mechanism by which vamorolone exerts its therapeutic effects in patients with DMD is unclear. In clinical studies, treatment with vamorolone induced a dose-dependent decrease in morning cortisol levels and a dosedependent increase in leukocyte and lymphocyte counts.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Vamorolone, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.